106 related articles for article (PubMed ID: 3246723)
1. [Acute myeloid leukemia six years after chemotherapy of Hodgkin's disease].
Fujii H; Yashige H; Maekawa T; Horiike S
Rinsho Ketsueki; 1988 Dec; 29(12):2369-74. PubMed ID: 3246723
[No Abstract] [Full Text] [Related]
2. [Acute myeloid leukemia after treatment of Hodgkin's disease].
Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukemia following therapy of Hodgkin's disease with radiotherapy and ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).
Lipton JH; Gospodarowicz M; Reingold S
Hematol Oncol; 1996 Mar; 14(1):29-31. PubMed ID: 8613133
[TBL] [Abstract][Full Text] [Related]
4. [Four cases of therapy-related leukemia in multiple myeloma].
Natori K; Izumi H; Kaneko K; Ishihara S; Nagase D; Fujimoto Y; Kato M; Umeda M; Kuraishi Y
Gan To Kagaku Ryoho; 2007 Jan; 34(1):121-4. PubMed ID: 17220686
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia following ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and radiotherapy for Hodgkin's disease.
Amadori S; Papa G; Anselmo AP; Fidani P; Mandelli F; Biagini C
Cancer Treat Rep; 1983 Jun; 67(6):603-4. PubMed ID: 6190561
[No Abstract] [Full Text] [Related]
6. Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Sonneveld P; Hop W; Mulder AH; Michiels JJ; Blijham G; van de Lelie J; Raemakers JW; Nieuwenhuis K; van der Heul C
Semin Hematol; 1994 Apr; 31(2 Suppl 3):9-12. PubMed ID: 8073309
[No Abstract] [Full Text] [Related]
7. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
8. [Alternating chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (CHOP); etoposide, procarbazine, vindesine and prednisolone (EPVP) as a treatment for advanced-stage Hodgkin's disease].
Kumagai K; Takagi T; Sakai C; Wakatsuki S
Gan To Kagaku Ryoho; 1996 Mar; 23(4):499-501. PubMed ID: 8678506
[No Abstract] [Full Text] [Related]
9. Hodgkin's disease and the risk of acute leukemia in successfully treated patients.
Valagussa P; Bonadonna G
Haematologica; 1998 Sep; 83(9):769-70. PubMed ID: 9825571
[No Abstract] [Full Text] [Related]
10. [Possibilities for the cure of acute myeloblastic leukemia with the modified VAPA regimen: preliminary results].
Díaz Mediavilla J; del Potro Gómez E; Llorente Pérez L; Martínez Martínez R; Guerra Moyano JL; de la Vega Bueno E; Alvarez Carmona A; Krsnik Castelló I; Alarcón Zurita C; Rodríguez Vázquez M
Med Clin (Barc); 1984 Dec; 83(19):783-6. PubMed ID: 6597329
[No Abstract] [Full Text] [Related]
11. Severe skin necrosis after rituximab-CHOP therapy.
Botden IP; Leys MB; van Houten AA; Peeters RP
Neth J Med; 2008 Nov; 66(10):448-9. PubMed ID: 19011274
[No Abstract] [Full Text] [Related]
12. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
13. [Secondary malignant tumors following treatment of Hodgkin's disease].
Shishkin IP
Med Radiol (Mosk); 1984 Aug; 29(8):24-8. PubMed ID: 6590941
[TBL] [Abstract][Full Text] [Related]
14. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
[No Abstract] [Full Text] [Related]
15. [Treating Hodgkin's disease: for whom the more means better?].
Illés A
Magy Onkol; 2004; 48(2):157-61. PubMed ID: 15351812
[TBL] [Abstract][Full Text] [Related]
16. Essential thrombocythemia after treatment of non-Hodgkin's lymphoma.
Maciel JF; de Lourdes Chauffaille M; Inaoka RJ; Colleoni GW; Yamamoto M
Leuk Res; 2007 Nov; 31(11):1593-5. PubMed ID: 17324461
[No Abstract] [Full Text] [Related]
17. Carcinogenesis in Hodgkin's disease.
Colman M
Hematol Oncol; 1984; 2(1):2-4. PubMed ID: 6588020
[No Abstract] [Full Text] [Related]
18. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
19. [Acute non-lymphatic leukemia after treatment of Hodgkin's lymphoma with chemotherapy and radiotherapy].
Lira P; Grebe G
Rev Med Chil; 1984 Oct; 112(10):1021-5. PubMed ID: 6085597
[No Abstract] [Full Text] [Related]
20. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
